{
    "clinical_study": {
        "@rank": "77355", 
        "arm_group": {
            "arm_group_label": "amlodipine/valsartan", 
            "arm_group_type": "Experimental", 
            "description": "All patients will receive amlodipine/valsartan 160/5 mg daily in screening and up titrated to amlodipine/valsartan 160/10 mg daily at visit 2 (day 30) if their hypertension can not be controlled. The duration of treatment period is 8 weeks."
        }, 
        "brief_summary": {
            "textblock": "The population that will be included in this study, will be regular Turkish hypertensive\n      patients who are expected to consume sodium in high amounts. It is hypothesized that, in\n      that population, amlodipine/valsartan will be effective at the same rate of blood pressure\n      (BP) control rate as expected from literature."
        }, 
        "brief_title": "Study of Efficacy and Safety of CVAA489 in Hypertensive Patients", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Essential Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female, above 18 years of age\n\n          -  Diagnosis of essential hypertension\n\n          -  Newly diagnosed,\n\n          -  Previously untreated, or Currently untreated (not on regular antihypertensive\n             treatment during the previous at least 1-month period)\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  Known or suspected secondary hypertension\n\n          -  eGFR lower than 30 mL/min\n\n          -  Use of any other hypertension treatments during the enrollment and need for using the\n             related treatments during the study phase\n\n          -  History of hypersensitivity to any of the study drugs or to drugs of similar chemical\n             classes. (i.e. valsartan, amlodipine, hydrochlorothiazide)\n\n          -  History of malignancy of any organ system (other than localized basal cell carcinoma\n             of the skin), treated or untreated, within the past 5 years, regardless of whether\n             there is evidence of local recurrence or metastases.\n\n          -  Use of other investigational drugs within 5 half-lives of enrollment, or within 30\n             days until the expected PD effect has returned to baseline, whichever is\n             longer.Pregnant or nursing (lactating) women\n\n          -  Other protocol-defined inclusion/exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "178", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02062645", 
            "org_study_id": "CVAA489ATR04"
        }, 
        "intervention": {
            "arm_group_label": "amlodipine/valsartan", 
            "description": "Fixed combination of amlodipine and valsartan in tablet; 160/5 mg, 160/10 mg", 
            "intervention_name": "amlodipine/valsartan", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Amlodipine", 
                "Valsartan", 
                "Amlodipine, valsartan drug combination"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "essential hypertension", 
        "lastchanged_date": "March 18, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Ankara", 
                        "country": "Turkey", 
                        "zip": "06100"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Canakkale", 
                        "country": "Turkey"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gaziantep", 
                        "country": "Turkey", 
                        "zip": "27070"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Istanbul", 
                        "country": "Turkey", 
                        "zip": "34303"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Istanbul", 
                        "country": "Turkey", 
                        "zip": "34093"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kinikli / Denizli", 
                        "country": "Turkey", 
                        "zip": "20070"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kocaeli", 
                        "country": "Turkey", 
                        "zip": "41380"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Malatya", 
                        "country": "Turkey", 
                        "zip": "44280"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mersin", 
                        "country": "Turkey", 
                        "zip": "33079"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Talas / Kayseri", 
                        "country": "Turkey", 
                        "zip": "38039"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Turkey"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Single-Arm Open-Label Multicenter Phase IV Clinical Trial to Explore the Blood Pressure Lowering Effect of Exforge\u00ae (Amlodipine/Valsartan: AMLO/VAL) in Hypertensive Patients", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+41613241111"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Turkey: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Control rate of BP defined as BP lower than 140/90 mmHg.", 
            "measure": "Percentage of patients with control rate of blood pressure (BP)", 
            "safety_issue": "No", 
            "time_frame": "2 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02062645"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "All patient will have office BP monitoring in the clinic in each visit.", 
                "measure": "Change from baseline in systolic blood pressure (SBP) in patients treated with valsartan/amlodipine at 2 months", 
                "safety_issue": "No", 
                "time_frame": "baseline, 2 months"
            }, 
            {
                "description": "All patient will have office BP monitoring in the clinic in each visit.", 
                "measure": "Change from baseline in diastolic blood pressure (DBP) in patients treated with valsartan/amlodipine at 2 months", 
                "safety_issue": "No", 
                "time_frame": "baseline, 2 months"
            }, 
            {
                "description": "All patient will have office BP monitoring in the clinic in each visit. Control rate of BP defined as BP lower than 140/90 mmHg.", 
                "measure": "Change from baseline control rate of BP in patients with high sodium intake at 2 months", 
                "safety_issue": "No", 
                "time_frame": "baseline, 2 months"
            }, 
            {
                "description": "All patients will have office BP monitoring in the clinic in each visit", 
                "measure": "Change from baseline in SBP and DBP in patients with high sodium intake", 
                "safety_issue": "No", 
                "time_frame": "baseline, 2 months"
            }, 
            {
                "measure": "Number of patients with total adverse events, serious adverse events and death to assess tolerability of valsartan/amlodipine", 
                "safety_issue": "Yes", 
                "time_frame": "2 months"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}